Pharmspective Will Feature Demo of Healthcare Reform App at Academy of Managed Care Pharmacy Conference in San Francisco April 18-20

NEW YORK, April 17, 2012 /PRNewswire/ -- The 24th Academy of Managed Care Pharmacy Meeting will take place from April 18-20, 2012 in San Francisco, CA and Specialty Therapeutics Market Research firm Pharmspective will be in attendance.  CEO Steve Reid and Chief Technology Officer Karl Kessler will share the company's latest knowledge management applications and syndicated research offerings with Managed Care and Pharma Payer Marketing decision makers. 

Reid and Kessler especially look forward to spending time with clients discussing Pharmspective's ClearView™ app, a knowledge management tool specifically developed to analyze provisions in the health care reform law and their impact on key pharma and MCO decision makers.  ClearView™ , a PC and iPad-friendly app, was designed as a strategic planning tool for payer and brand marketing leaders, and has also emerged as a training resource for account managers and pharmacy decision-makers seeking a comprehensive understanding of healthcare reform and its' real-world implications for their roles. 

"Hoping that the Supreme Court will make Healthcare Reform go away is not an option," which Reid says some in the industry are counting on.  "Regardless of how the court rules, many of the provisions of Healthcare Reform are already in place and the momentum for other changes is strong.  It is unlikely that we will be completely starting over in July, after the decision, so helping our clients build a framework to plan for the coming changes and prepare their commercial organizations for a new customer landscape is one of our top priorities."

 "ClearView™ translates the healthcare reform legislation through a dynamic, intuitive web app that lets the user browse and search the legislation, link to news articles and background material,  and collaborate with planning teams to assess and define the commercial impact of the law on pharma brands," says Kessler.

Reid and Kessler also plan to discuss a range of issues related to Specialty Therapeutics access and reimbursement.  Pharmspective recently released Rheumatoid Arthritis Adoption Insights, its' first syndicated report focused on Specialty Therapeutics and the prescriber decision-making process. Growing payer influence on the prescribing decision to utilize targeted therapies is a key focus of Pharmspective Adoption Insights Reports.  (Future Reports will assess prescriber decision-making for Cancer Molecular Diagnostics-5/7/2012, Psoriasis, Multiple Sclerosis, Crohn's/UC, Lupus, and Oncology) 

The Pharsmpective team will set up shop at booth 439 in the Moscone West Convention Center.  As AMCP focuses on helping their members address emerging issues in managing utilization of Specialty Therapeutics, Reid says he believes that Pharmspective is well-equipped to provide unique insights to the pharmaceutical and Managed Care industries through cutting-edge knowledge management apps that will help customers understand the factors influencing the Specialty Therapeutics Buying Process. 

About Pharmspective: Pharmspective, LLC (www.pharmspective.com) is a specialty therapeutics market research firm providing commercial insights and knowledge management applications for the biopharmaceutical industry. The company is uniquely focused on understanding the buying process for specialty therapeutics through syndicated market research studies examining clinical decision-making, drug acquisition, access and reimbursement, and patient administration for specialty therapeutics in autoimmune diseases (rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's/UC, lupus) and oncology.  Pharmspective's proprietary knowledge management applications create a superior user experience and include the ClearView™ Healthcare Reform app. Pharmspective™ is a trademark of Pharmspective, LLC. Follow Pharmspective on twitter.com/Pharmspective. The company maintains offices in New York City and St. Louis, MO. 

Contact: Jennifer Strathmann Tel: 314-814-2729 x1002 [email protected]

SOURCE Pharmspective, LLC